Febuxostat, a selective and potent inhibitor of xanthine oxidase (XO), can alleviate AKI, which may be related to antioxidant stress, anti-inflammation, and antiendoplasmic reticulum stress and reducing uric acid production [47–49]. The gene discussed is XDH; the disease is acute kidney injury.